GRETCHEN MARTIN: Open Payments
NPI 1912078585 · PITTSBURG, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$709 in 41 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $436 · 2025 $709
Food & beverage: $709
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $220 |
| Astellas Pharma US Inc | 3 | $76 |
| Lundbeck LLC | 2 | $53 |
| AstraZeneca Pharmaceuticals LP | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Novo Nordisk Inc | 2 | $38 |
| Lilly USA, LLC | 2 | $37 |
| PFIZER INC. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $23 |
Products named: REXULTI, UBRELVY, Veozah, QULIPTA, VRAYLAR, MOUNJARO, FARXIGA, PREVNAR 20.
Industry payments across KS — which companies pay providers there.
